Lilly gets sought-after FDA designation for Alzheimer's candidate
![Photo: Mike Blake/REUTERS / X00030](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13084266.ece/ALTERNATES/schema-16_9/doc7gd5belgn2qyu91agce.jpg)
Eli Lilly's drug candidate donanemab treating Alzheimer's disease has received breakthrough therapy status at the US Food and Drug Administration, according to a press release from Eli Lilly.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.